Corrigendum to: Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon-like peptide-1 secretion (Diabetes, Obesity and Metabolism, (2016), 18, 6, (571-580), 10.1111/dom.12648);Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon-like peptide-1 secretion

Diabetes, Obesity and Metabolism

Volumn 18, Issue 6, 2016, Pages 571-580

  Hansen, M ^a,b   Scheltema, M J ^a,c   Sonne, D P ^a,b   Hansen, J S ^a   Sperling, M ^a   Rehfeld, J F ^a   Holst, J J ^b   Vilsboll T ^a   Knop, F K ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

antidiabetic drug; drug development; GLP 1; glucose metabolism; type 2 diabetes

Indexed keywords

BILE ACID; C PEPTIDE; CHENODEOXYCHOLIC ACID; CHOLECYSTOKININ; COLESEVELAM; GASTRIC INHIBITORY POLYPEPTIDE; GASTRIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PARACETAMOL; PLACEBO; GLUCOSE BLOOD LEVEL; INCRETIN;

ADULT; APPETITE; ARTICLE; BILE ACID BLOOD LEVEL; BLOOD SAMPLING; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIGESTIVE TRACT PARAMETERS; DOUBLE BLIND PROCEDURE; FOOD INTAKE; GALLBLADDER VOLUME; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL; STOMACH EMPTYING; AGED; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG EFFECTS; FEMALE; GLUCOSE BLOOD LEVEL; MALE; METABOLISM; MIDDLE AGED; SECRETION (PROCESS);

AGED; BILE ACIDS AND SALTS; BLOOD GLUCOSE; C-PEPTIDE; CHENODEOXYCHOLIC ACID; COLESEVELAM HYDROCHLORIDE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GASTRIC EMPTYING; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; INSULIN; MALE; MIDDLE AGED; PLACEBOS;

EID: 84961784129     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13187     Document Type: Erratum

References (44)

1. Parks DJ, Blanchard SG, Bledsoe RK et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999; 284: 1365–1368.
2. Maruyama T, Miyamoto Y, Nakamura T et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun 2002; 298: 714–719.
3. Zhang Y, Lee FY, Barrera G et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A 2006; 103: 1006–1011.
4. Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun 2005; 329: 386–390.
5. Trabelsi M-S, Daoudi M, Prawitt J et al. Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. Nat Commun 2015; 6: 7629.
6. Holst JJ. On the physiology of GIP and GLP-1. Horm Metab Res 2004; 36: 747–754.
7. Parker HE, Wallis K, le Roux CW, Wong KY, Reimann F, Gribble FM. Molecular mechanisms underlying bile acid-stimulated glucagon-like peptide-1 secretion. Br J Pharmacol 2012; 165: 414–423.
8. Adrian TE, Ballantyne GH, Longo WE et al. Deoxycholate is an important releaser of peptide YY and enteroglucagon from the human colon. Gut 1993; 34: 1219–1224.
9. Adrian TE, Gariballa S, Parekh KA et al. Rectal taurocholate increases L cell and insulin secretion, and decreases blood glucose and food intake in obese type 2 diabetic volunteers. Diabetologia 2012; 55: 2343–2347.
10. Wu T, Bound MJ, Standfield SD et al. Effects of rectal administration of taurocholic acid on glucagon-like peptide-1 and peptide YY secretion in healthy humans. Diabetes Obes Metab 2013; 15: 474–477.
11. Meyer-Gerspach AC, Steinert RE, Keller S, Malarski A, Schulte FH, Beglinger C. Effects of chenodeoxycholic acid on the secretion of gut peptides and fibroblast growth factors in healthy humans. J Clin Endocrinol Metab 2013; 98: 3351–3358.
12. Wu T, Bound MJ, Standfield SD, Jones KL, Horowitz M, Rayner CK. Effects of taurocholic acid on glycemic, glucagon-like peptide-1, and insulin responses to small intestinal glucose infusion in healthy humans. J Clin Endocrinol Metab 2013; 98: E718–E722.
13. Brighton CA, Rievaj J, Kuhre RE et al. Bile acids trigger GLP-1 release predominantly by accessing basolaterally located G protein-coupled bile acid receptors. Endocrinology 2015; 156: 3961–3970.
14. Hodge RJ, Lin J, Vasist Johnson LS et al. Safety, pharmacokinetics, and pharmacodynamic effects of a selective TGR5 agonist, SB-756050, in type 2 diabetes. Clin Pharmacol Drug Dev 2013; 2: 213–222.
15. Hodge RJ, Nunez DJ. Therapeutic potential of TGR5 agonists. Hope or hype? Diabetes Obes Metab 2016. Accepted Article. DOI: 10.1111/dom.12636.
16. Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med 2008; 168: 1975–1983.
17. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38: 140–149.
18. Beysen C, Murphy EJ, Deines K et al. Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study. Diabetologia 2012; 55: 432–442.
19. Smushkin G, Sathananthan M, Piccinini F et al. The effect of a bile acid sequestrant on glucose metabolism in subjects with type 2 diabetes. Diabetes 2013; 62: 1094–1101.
20. Potthoff MJ, Potts A, He T et al. Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice. Am J Physiol Gastrointest Liver Physiol 2013; 304: G371–G380.
21. Prawitt J, Caron S, Staels B. Glucose-lowering effects of intestinal bile acid sequestration through enhancement of splanchnic glucose utilization. Trends Endocrinol Metab 2014; 25: 235–244.
22. Medhus AW, Lofthus CM, Bredesen J, Husebye E. Gastric emptying: the validity of the paracetamol absorption test adjusted for individual pharmacokinetics. Neurogastroenterol Motil 2001; 13: 179–185.
23. Flint A, Raben A, Blundell JE, Astrup A. Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies. Int J Obes Relat Metab Disord 2000; 24: 38–48.
24. Hare KJ, Knop FK, Asmar M et al. Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus. J Clin Endocrinol Metab 2009; 94: 4679–4687.
25. Krarup T, Holst JJ. The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera. Regul Pept 1984; 9: 35–46.
26. Stadil F, Rehfeld JF. Determination of gastrin in serum. An evaluation of the reliability of a radioimmunoassay. Scand J Gastroenterol 1973; 8: 101–112.
27. Orskov C, Jeppesen J, Madsbad S, Holst JJ. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest 1991; 87: 415–423.
28. Miceli JN, Aravind MK, Cohen SN, Done AK. Simultaneous measurements of acetaminophen and salicylate in plasma by liquid chromatography. Clin Chem 1979; 25: 1002–1004.
29. Dodds WJ, Groh WJ, Darweesh RM, Lawson TL, Kishk SM, Kern MK. Sonographic measurement of gallbladder volume. Am J Roentgenol 1985; 145: 1009–1011.
30. Kawamata Y, Fujii R, Hosoya M et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem 2003; 278: 9435–9440.
31. Hansen M, Sonne DP, Knop FK. Bile acid sequestrants: glucose-lowering mechanisms and efficacy in type 2 diabetes. Curr Diab Rep 2014; 14: 482.
32. Harach T, Pols TWH, Nomura M et al. TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. Sci Rep 2012; 2: 430.
33. Habib AM, Richards P, Cairns LS et al. Overlap of endocrine hormone expression in the mouse intestine revealed by transcriptional profiling and flow cytometry. Endocrinology 2012; 153: 3054–3065.
34. Björnsson OG, Fletcher DR, Christofides ND, Bloom SR, Chadwick VS. Duodenal perfusion with sodium taurocholate inhibits biliary but not pancreatic secretion in man. Clin Sci 1982; 62: 651–659.
35. Maruyama T, Tanaka K, Suzuki J et al. Targeted disruption of G protein-coupled bile acid receptor 1 (Gpbar1/M-Bar) in mice. J Endocrinol 2006; 191: 197–205.
36. Kumar DP, Rajagopal S, Mahavadi S et al. Activation of transmembrane bile acid receptor TGR5 stimulates insulin secretion in pancreatic β cells. Biochem Biophys Res Commun 2012; 427: 600–605.
37. Kumar D, Mahavadi S, Mirshahi F, Grider J, Murthy K, Sanyal A. Expression and function of bile acid receptor TGR5 in glucagon secreting pancreatic α cells: hyperglycemia induced expression of PC1 and release of GLP-1 in response to activation of TGR5 by bile acids (1108.6). FASEB J 2014; 28(Suppl. 1): 1108.6.
38. Holst JJ. Gut glucagon, enteroglucagon, gut glucagonlike immunoreactivity, glicentin–current status. Gastroenterology 1983; 84: 1602–1613.
39. Sonne DP, Rehfeld JF, Holst JJ, Vilsbøll T, Knop FK. Postprandial gallbladder emptying in patients with type 2 diabetes: potential implications for bile-induced secretion of glucagon-like peptide 1. Eur J Endocrinol 2014; 171: 407–419.
40. Penagini R, Misiewicz JJ, Frost PG. Effect of jejunal infusion of bile acids on small bowel transit and fasting jejunal motility in man. Gut 1988; 29: 789–794.
41. Jones KL, Horowitz M, Carney BI, Wishart JM, Guha S, Green L. Gastric emptying in early noninsulin-dependent diabetes mellitus. J Nucl Med 1996; 37: 1643–1648.
42. Psichas A, Little T, Lal S, McLaughlin J. Colestyramine slows gastric emptying of liquids and reduces appetite in healthy subjects. Neurogastroenterol Motil 2012; 24: 1095–1101.
43. Schittenhelm B, Wagner R, Kähny V et al. Role of FXR in β-cells of lean and obese mice. Endocrinology 2015; 156: 1263–1271.
44. Napolitano A, Miller S, Nicholls AW et al. Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. PLoS One 2014; 9: e100778.